WO2009059242A8 - A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use - Google Patents

A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use Download PDF

Info

Publication number
WO2009059242A8
WO2009059242A8 PCT/US2008/082139 US2008082139W WO2009059242A8 WO 2009059242 A8 WO2009059242 A8 WO 2009059242A8 US 2008082139 W US2008082139 W US 2008082139W WO 2009059242 A8 WO2009059242 A8 WO 2009059242A8
Authority
WO
WIPO (PCT)
Prior art keywords
glycine agonist
partial glycine
levodopa
disease
administration
Prior art date
Application number
PCT/US2008/082139
Other languages
French (fr)
Other versions
WO2009059242A1 (en
Inventor
Roberto Fiorentini
Original Assignee
Lazarus Therapeutics Inc
Roberto Fiorentini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lazarus Therapeutics Inc, Roberto Fiorentini filed Critical Lazarus Therapeutics Inc
Publication of WO2009059242A1 publication Critical patent/WO2009059242A1/en
Publication of WO2009059242A8 publication Critical patent/WO2009059242A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprises partial glycine agonist in a controlled release formulation for once a day administration to subjects with Parkinson's disease. The composition includes a controlled release material comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 μg/mL and not more than 30 μg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 μg/mL for 12 - 16 hours. The partial glycine agonist is administered in a dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa. A method for treating Parkinson's disease in a subject comprises administering levodopa to the patient at least once per day and administering to the patient a once daily composition including a partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose for up to 16 hours after administration of the partial glycine agonist.
PCT/US2008/082139 2007-11-01 2008-10-31 A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use WO2009059242A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US151507P 2007-11-01 2007-11-01
US61/001,515 2007-11-01

Publications (2)

Publication Number Publication Date
WO2009059242A1 WO2009059242A1 (en) 2009-05-07
WO2009059242A8 true WO2009059242A8 (en) 2009-07-16

Family

ID=40591504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082139 WO2009059242A1 (en) 2007-11-01 2008-10-31 A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use

Country Status (1)

Country Link
WO (1) WO2009059242A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069773A1 (en) * 2013-11-05 2015-05-14 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
JP6982870B2 (en) 2015-05-06 2021-12-17 シンアジャル コーポレイション Pharmaceutical suspensions containing drug particles, devices for their administration, and how to use them
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
CN111643493B (en) * 2020-05-26 2023-01-10 上海京新生物医药有限公司 High-concentration levodopa preparation and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
CA2494707A1 (en) * 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease

Also Published As

Publication number Publication date
WO2009059242A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CA2588296A1 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2012007159A3 (en) Novel gastro-retentive dosage forms
IL192104A (en) Formulation suitable for subcutaneous administration comprising ctla4ig molecules, sugar and a pharmaceutically acceptable aqueous carrier and use thereof for preparation of a medicament
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MY142204A (en) Pramipexole once-daily dosage form
MX2009013574A (en) Modified release solid or semi-solid dosage forms.
WO2008019996A3 (en) Formulations of flibanserin and method for manufacturing the same
WO2008069941A3 (en) Modified release ibuprofen solid oral dosage form
MX2009005339A (en) Modified release analgesic suspensions.
MX2010013766A (en) Rasagiline for parkinson's disease modification.
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
NZ606383A (en) Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2008060764A3 (en) Topical therapies for oral mucositis and other conditions
EP1849462A3 (en) A method of alleviating signs and symptons of Spasticity
US20110275693A1 (en) Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives
MY144021A (en) Pharmaceutical delivery system
WO2009059242A8 (en) A controlled-release partial glycine agonist composition for use with levodopa in parkinson's disease and method of use
AU2019205327A8 (en) Intranasal delivery of levodopa powder by precision olfactory device
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2007149366B1 (en) Prolonged improvement of renal function comprising infrequent administration of an aa1ra
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846073

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 08846073

Country of ref document: EP

Kind code of ref document: A1